Google allows advertisers to target the sensitive informational queries of cancer patients DOI Creative Commons
Marco Zenone, Alessandro R Marcon, Nora Kenworthy

et al.

Published: Dec. 23, 2024

Alternative cancer treatments are associated with earlier time to death when used without evidence-based treatments. Our study suggests alternative clinics providing scientifically unsupported spent an estimated $15,839,504 on Google ads from 2012 2023 targeting users in the United States. The led 6,717,663 website visits. Paid traffic constituted 44.4% of all traffic. Advertisers targeted patients using Google’s keyword matching feature which matches ad keywords searches users. Keywords selected by advertisers mimicked sensitive informational search queries patients. In 2023, 20,035 unique emulated prognosis, treatments, accessing treatment, treatment options, diagnosis, specific cancers, and late-stage cancer.

Language: Английский

COVID-19 and Rates of Cancer Diagnosis in the US DOI Creative Commons
Todd Burus, Feitong Lei, Bin Huang

et al.

JAMA Network Open, Journal Year: 2024, Volume and Issue: 7(9), P. e2432288 - e2432288

Published: Sept. 6, 2024

Importance US cancer diagnoses were substantially lower than expected during the COVID-19 pandemic in 2020. A national study on extent to which rates recovered 2021 has not yet been conducted. Objective To examine observed vs rate trends for January 2020 December 2021. Design, Setting, and Participants This cross-sectional, population-based of incidence used Surveillance, Epidemiology, End Results 22 (SEER-22) Registries Database, covers 47.9% population. Included individuals those with an invasive diagnosis reported registries included SEER-22 between 1, 2000, 31, Exposures Age, sex, race ethnicity, urbanicity, stage at diagnosis. Main Outcomes Measures Expected measured years from prepandemic using ensemble forecasting methods. Relative difference numbers potentially missed cases measured. The 1 578 697 2021, including 798 765 among male (50.6%) 909 654 persons aged 65 or older (57.6%). Observed all-sites by 9.4% (95% prediction interval [PI], 8.5%-10.5%), 2.7% PI, 1.4%-3.9%), 6.0% across both combined 5.1%-7.1%), resulting 149 577 undiagnosed 126 059-176 970). Of 4 screening-detected cancers, only female breast showed significant recovery exceeding 2.5% 0.1%-4.8%), while reductions remained lung (9.1% expected; 95% 6.4%-13.2%) cervical (4.5% 0.4%-8.0%), particularly early Rates returned individuals, younger years, non-Hispanic Asian Pacific Islander ethnicity. Conclusions Relevance cross-sectional found that improved but continued be expected, adding existing deficit diagnosed Particular attention should directed strategies immediately increase screenings make up lost ground.

Language: Английский

Citations

7
Declining Incidence of Childhood Cancers: An Updated Analysis of the National Childhood Cancer Registry Data (2018–2021) DOI Open Access
Jason Semprini

Pediatric Blood & Cancer, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 4, 2025

The authors declare no conflicts of interest. data that support the findings this study are available from NCCR. Restrictions apply to availability these data, which were used under license for study. Data https://seer.cancer.gov/data-software/documentation/seerstat/nccr/ with permission Please note: publisher is not responsible content or functionality any supporting information supplied by authors. Any queries (other than missing content) should be directed corresponding author article.

Language: Английский

Citations

0
Changes in cancer incidence and stage during the COVID-19 pandemic in 2020–2021 in the Nordic countries DOI Creative Commons
Anna L.V. Johansson,

Anna Skog,

Tom Børge Johannesen

et al.

Acta Oncologica, Journal Year: 2025, Volume and Issue: 64, P. 257 - 266

Published: Feb. 12, 2025

Background and purpose: The COVID-19 pandemic impacted substantially on cancer healthcare, including the temporary suspension of screening activities. We compared incidence rates stage during 2020–2021 to pre-pandemic in Nordic countries. Material methods: Using data from national registries Denmark, Finland, Iceland, Norway, Sweden, we estimated age-, sex-, period-adjusted rate ratios, expressed as relative percentage change (%) with 95% confidence intervals (CIs), comparing those 2017–2019 (pre-pandemic). Results: In 2020–2021, 340,675 cases were diagnosed. declined first wave (Q2 2020), ranging –21.7% [95% CI: –23.3%; –20.2%] (Sweden) –7.9% [–17.7%; 3.0%] (Iceland). Incidence also second (Q1 2021), –8.6% [–10.2%; –6.9%] –2.3% [–4.6%; 0.1%] (Norway), Sweden by –3.1% [–4.8%; –1.3%] third (Q4 2021). Stage I breast 2020 Denmark/Norway/Sweden, some catch-up II 2021. Prostate Denmark/Finland/Norway/Sweden while melanoma Finland 2020. During 2020, colon Denmark rectal lung kidney Norway. Interpretation: across countries largest declines Sweden. wave, mostly similar rates. Changes may reflect reduced

Language: Английский

Citations

0
History, clinical presentation, therapy, and patient reported outcomes of mucosal lichen planus: a cross‐sectional study DOI Creative Commons
Neda Cramer, Daniel Kromer,

Julia M. Bootsveld

et al.

JDDG Journal der Deutschen Dermatologischen Gesellschaft, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 16, 2025

Mucosal lichen planus (LP) is a chronic inflammatory disease. The patient's journey can be arduous as diagnosis and therapy are challenging. In this cross-sectional study, wide range of characteristics the were assessed evaluated from total 72 patients with mucosal LP who treated in dermatology departments six German university medical centers between 02/2022 07/2023. On average, 18.1 months elapsed onset symptoms diagnosis. Until correct was made, an average 3.1 different physicians same or specialties consulted. 28.1% also had cutaneous involvement. Therapeutically, 68% received at least one systemic drug. Both topical (90%, 65/72) (oral, 50% patients, 36/72; intravenous, 33%, 24/72) glucocorticoids most frequently used. Systemic agents often discontinued due to ineffectiveness (46%, 50/110). Satisfaction treatment highest for intravenous (moderate high satisfaction: 59% 36%, respectively), lowest retinoids 8%. This study indicates that there might lack diagnostic awareness among unmet need effective options.

Language: Английский

Citations

0
The Rebound Effect of the COVID-19 Pandemic on Clinically Significant Prostate Cancer Diagnosis DOI Creative Commons

Antonio Fanelli,

Ugo Giovanni Falagario, Marco Finati

et al.

Applied Sciences, Journal Year: 2025, Volume and Issue: 15(6), P. 3100 - 3100

Published: March 12, 2025

Background and aim: The effect of the COVID-19 pandemic on delayed screening consequent diagnosis prostate cancer (PCa) is yet to be defined. This study aimed evaluate impact PCa by comparing number biopsies performed observing detection rate during pre-COVID, COVID post-COVID periods. Materials Methods: A prospectively maintained database was queried identify patients who received biopsy between January 2018 December 2022. cohort stratified into periods based Italian government regulations. primary outcomes were clinically significant (csPCa) in each period. Changes median evaluated using Kruskal–Wallis test, whereas changes csPCa chi-square test. loess function depicted across Results: Overall, 2502 included; their age 68 (62–74) years. period 46 (43–56), 39 (27–43) (40–58), respectively (p = 0.02). most decrease observed peak pandemic, from March May 2020. three 37%, 34% 39%, 0.01). demonstrated a rebound diagnosed starting November 2020, while same not for non-cs PCa. Conclusion: caused diagnosed. We after pandemic. Future studies with longer follow-ups are needed address effects grade migration burden treatment oncological outcomes.

Language: Английский

Citations

0
JAMA Oncology—The Year in Review, 2024 DOI
Mary L. Disis

JAMA Oncology, Journal Year: 2025, Volume and Issue: unknown

Published: March 20, 2025

Language: Английский

Citations

0
Anamnese, klinische Merkmale, Therapie und patientenberichtete Ergebnisse bei Lichen ruber mucosae: Eine Querschnittsstudie DOI Creative Commons
Neda Cramer, Daniel Kromer,

Julia M. Bootsveld

et al.

JDDG Journal der Deutschen Dermatologischen Gesellschaft, Journal Year: 2025, Volume and Issue: 23(4), P. 449 - 464

Published: April 1, 2025

Zusammenfassung Hintergrund Der Lichen ruber mucosae (LRM) ist eine chronische entzündliche Erkrankung. Weg des Patienten mit der Krankheit kann schwierig sein, da die Diagnosestellung und Therapie Herausforderung darstellen. Methodik In dieser Querschnittsstudie wurden bei insgesamt 72 LRM, zwischen 02/2022 07/2023 in den dermatologischen Abteilungen von sechs deutschen Universitätskliniken behandelt wurden, Vielzahl Charakteristika zum Krankheitsverlauf erfasst ausgewertet. Ergebnisse Zwischen dem Auftreten Symptome lagen im Durchschnitt 18,1 Monate. Bis zur korrekten durchschnittlich 3,1 verschiedene Ärzte gleichen oder anderer Fachrichtungen konsultiert. 28,1% hatten auch Hautbeteiligung. Therapeutisch erhielten 68% mindestens ein systemisches Medikament. Sowohl topische (90%, 65/72) als systemische (oral, 50%, 36/72; intravenös, 33%, 24/72) Glukokortikoide am häufigsten eingesetzt. Systemische Medikamente wegen Unwirksamkeit abgesetzt (46%, 50/110). Die Zufriedenheit Behandlung war intravenösen topischen Glukokortikoiden höchsten (mittlere bis hohe Zufriedenheit: 59% bzw. 36%) Retinoiden 8% niedrigsten. Schlussfolgerungen Studie deuten darauf hin, dass das diagnostische Bewusstsein möglicherweise unzureichend Bedarf an wirksamen systemischen Therapien besteht.

Citations

0
Recovery From COVID-19–Related Disruptions in Cancer Detection DOI Creative Commons
Uriel Kim, Johnie Rose, Bryan T. Carroll

et al.

JAMA Network Open, Journal Year: 2024, Volume and Issue: 7(10), P. e2439263 - e2439263

Published: Oct. 14, 2024

The COVID-19 pandemic impacted the timely diagnosis of cancer, which persisted as second leading cause death in US throughout pandemic.

Language: Английский

Citations

3
Underdiagnosed cancer during COVID‐19 pandemic and return to normality DOI
Antonio V. Sterpetti, Raimondo Gabriele, Immacolata Iannone

et al.

International Journal of Cancer, Journal Year: 2024, Volume and Issue: 155(6), P. 1139 - 1140

Published: April 29, 2024

Language: Английский

Citations

2
Determinants of Breast Cancer Screening Adherence During the COVID-19 Pandemic in a Cohort at Increased Inherited Cancer Risk in the United States DOI Creative Commons
Adrian Harris, Jemar R. Bather, Kensaku Kawamoto

et al.

Cancer Control, Journal Year: 2024, Volume and Issue: 31

Published: Jan. 1, 2024

Background We examined neighborhood characteristics concerning breast cancer screening annual adherence during the COVID-19 pandemic. Methods analyzed 6673 female patients aged 40 or older at increased inherited risk in 2 large health care systems (NYU Langone Health [NYULH] and University of Utah [UHealth]). Multinomial models were used to identify predictors mammogram groups (non-adherent, pre-pandemic adherent, pandemic period adherent) comparison adherent females. Potential determinants included sociodemographic factors. Results Comparing each group reference group, a reduced likelihood being non-adherent was associated with age (OR: 0.97, 95% CI: 0.95, 0.99), greater number relatives 0.80, 0.75, 0.86), seen NYULH study site 0.42, 0.29, 0.60). More correlated lesser 0.89, 0.81, 0.97). A lower areas less education 0.77, 0.62, 0.96) 0.35, 0.22, 0.55). Finally, deprivation 1.47, 1.08, 2.01) non-adherent. Conclusion Breast older, having more cancer, residing educational attainment, NYULH; non-adherence linked deprivation. These findings may mitigate clinically important delays times disruptions population for cancer.

Language: Английский

Citations

2